Continued treatment study for people who benefited from anifrolumab
Treatments studied
Part of Immune system & allergy clinical trials.
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the entire earlier study and received at least one dose of anifrolumab.
- Your doctor must think that continuing anifrolumab is more helpful than risky for you.
- You must be able to follow the study's rules and give your informed consent.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have any other medical condition (like cancer or hepatitis) that could make it unsafe for you to participate.
- You must not have stopped the earlier study early or have any ongoing side effects that would prevent restarting the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study looks at how well anifrolumab works for people with lupus in everyday medical care, not just in a research lab. It may help you if your doctor has decided to prescribe anifrolumab for the first time.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
This trial tests anifrolumab, an investigational drug that may help reduce lupus activity in people with moderate-to-severe disease. If you have active lupus despite current treatments, this study might offer a new option.
Hear when a new Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.